Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,725 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
P2X3 receptor antagonist in chronic cough--Authors' reply.
Smith JA, Abdulqawi R, Dockry R, Holt K, Layton G, McCarthy BG, Ford AP. Smith JA, et al. Lancet. 2015 Jul 18;386(9990):244-5. doi: 10.1016/S0140-6736(15)61275-2. Lancet. 2015. PMID: 26194520 No abstract available.
Gefapixant in two randomised dose-escalation studies in chronic cough.
Smith JA, Kitt MM, Butera P, Smith SA, Li Y, Xu ZJ, Holt K, Sen S, Sher MR, Ford AP. Smith JA, et al. Among authors: smith sa. Eur Respir J. 2020 Mar 20;55(3):1901615. doi: 10.1183/13993003.01615-2019. Print 2020 Mar. Eur Respir J. 2020. PMID: 31949115 Free article. Clinical Trial.
Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
Smith JA, Kitt MM, Morice AH, Birring SS, McGarvey LP, Sher MR, Li YP, Wu WC, Xu ZJ, Muccino DR, Ford AP; Protocol 012 Investigators. Smith JA, et al. Lancet Respir Med. 2020 Aug;8(8):775-785. doi: 10.1016/S2213-2600(19)30471-0. Epub 2020 Feb 25. Lancet Respir Med. 2020. PMID: 32109425 Clinical Trial.
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.
Muccino DR, Morice AH, Birring SS, Dicpinigaitis PV, Pavord ID, Assaid C, Kleijn HJ, Hussain A, La Rosa C, McGarvey L, Smith JA. Muccino DR, et al. Among authors: smith ja. ERJ Open Res. 2020 Nov 2;6(4):00284-2020. doi: 10.1183/23120541.00284-2020. eCollection 2020 Oct. ERJ Open Res. 2020. PMID: 33263037 Free PMC article.
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J, Nguyen AM, Li Q, Tzontcheva A, Iskold B, Green SA, Rosa C, Muccino DR, Smith JA; COUGH-1 and COUGH-2 Investigators. McGarvey LP, et al. Among authors: smith ja. Lancet. 2022 Mar 5;399(10328):909-923. doi: 10.1016/S0140-6736(21)02348-5. Lancet. 2022. PMID: 35248186 Clinical Trial.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough.
McGarvey L, Smith JA, Morice A, Birring SS, Chung KF, Dicpinigaitis PV, Niimi A, Benninger MS, Sher M, Matsunaga Y, Miyazaki S, Machida M, Ishihara H, Mahmood A, Gomez JC. McGarvey L, et al. Among authors: smith ja. Lung. 2023 Feb;201(1):25-35. doi: 10.1007/s00408-022-00592-5. Epub 2022 Dec 13. Lung. 2023. PMID: 36512069 Free PMC article. Clinical Trial.
3,725 results